James Mackay

James Mackay is the Co-Founder, President, and CEO of Crystalys Therapeutics Inc., bringing a distinguished background as a scientist and business leader in the global life sciences sector. With a proven track record of successfully bringing multiple drugs to market, they have led significant initiatives, including a $1.2B acquisition of Ardea Biosciences and FDA approval for Zurampic, the first novel treatment for gout in over 50 years. Mackay has held several key positions at AstraZeneca, including Global Product Vice President, where they developed strategies that enhanced the company's pharmaceutical portfolio. They actively contribute to various boards and advisory roles, demonstrating a commitment to both innovation in drug development and community engagement in the San Diego area. James holds a 1st Class degree from the University of Aberdeen.